Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 50.0% in May

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) saw a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 27,683 shares, a decline of 50.0% from the May 14th total of 55,395 shares. Based on an average trading volume of 135,751 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s stock are sold short.

Lonza Group Price Performance

LZAGY stock traded up $0.61 during midday trading on Monday, reaching $62.14. 60,218 shares of the company’s stock traded hands, compared to its average volume of 70,535. The firm’s fifty day moving average price is $63.13 and its 200-day moving average price is $65.48. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. Lonza Group has a 52 week low of $58.53 and a 52 week high of $73.85.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Read Our Latest Research Report on Lonza Group

About Lonza Group

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.